Article Text

Download PDFPDF
Diagnostic and therapeutic challenges in a recurrent endometrial carcinoma in lung, 15 years after primary treatment
  1. Amitabh Kumar Upadhyay1,
  2. Manoj Kumar1,
  3. Aaditya Prakash2 and
  4. Abhishek Kumar3
  1. 1Medical Oncology, Tata Main Hospital, Jamshedpur, Jharkhand, India
  2. 2Radiation Oncology, Tata Main Hospital, Jamshedpur, Jharkhand, India
  3. 3Nuclear Medicine, Tata Main Hospital, Jamshedpur, Jharkhand, India
  1. Correspondence to Dr Amitabh Kumar Upadhyay; dramit1111{at}gmail.com

Abstract

Endometrial carcinoma (EC) is the sixth most common cancer in females. Most ECs are detected in stage 1 and have a 5-year survival rate of more than 90%. Recurrence rates are highest within 5 years after treatment and are exceptionally rare after 10 years. Here, we describe a woman in her late 70s with endometrial cancer who was treated in 2008 and was diagnosed with a relapse in her left lung in 2023. Due to her advanced age and comorbidities, she was deemed inoperable. However, she received sequential chemotherapy and radiotherapy with a good partial response. She has now been started on hormonal therapy with an alternate megestrol and tamoxifen regime. There is a lack of follow-up imaging guidelines to detect late relapse, a dilemma in preferred treatment sequencing at relapse and an enigma in selecting chemotherapy or hormonal therapy.

  • Uterus
  • Estrogens
  • Cancer - see Oncology

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors The following authors were responsible for the drafting of the text, sourcing and editing of clinical images, investigation results, drawing original diagrams and algorithms and critical revision for important intellectual content: AKU, MK, AP and AK. The following authors gave final approval of the manuscript: AKU, MK, AP and AK.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.